Possible hemophilia cure under study in Israeli hospital
US biotech company BioMarin enlists aid of Sheba Medical Center to take part in international trials of a ‘magic bullet’ treatment for hemophilia A.
By ISRAEL21c —— Bio and Archives--January 24, 2018
Health and Medicine | Comments | Back To Full Article
Is a cure for hemophilia on the horizon? American biotechnology company BioMarin aims to find out with the help of Sheba Medical Center in Ramat Gan, Israel.
BioMarin has chosen Sheba to take part in the next phase of international trials for what’s being touted as a “magic bullet” cure for hemophilia A, a genetic blood-clotting deficiency that results in patients bleeding longer after an injury and more easily bruising. Hemophilia A, which affects mostly men, can be life-threatening.
Welcome to CFP’s Comment Section!
The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.
Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.
Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.
We ask only that commenters keep it civil, keep it clean.
Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.
READ OUR Commenting Policy